Fierce Innovation Awards Recognize Xcellerate® Trial Design As Best Data Analytics/Business Intelligence Technology

Covance is proud to announce that Xcellerate® Trial Design has been selected as the Fierce Innovation Awards Recognize Xcellerate® Trial Design winner of the Fierce Innovation Awards: Life Sciences Edition in the Data Analytics/Business Intelligence category. The Fierce Innovation Awards: Life Sciences Edition recognizes outstanding innovations that are driving improvements and transforming the life sciences industry. Xcellerate Trial Design was recognized for its innovative approach to improving site selection, forecasting resource demand and optimizing of clinical trial design. Continue reading

Computerworld Names Dimitris Agrafiotis of Covance a 2017 Premier 100 Technology Leader

Agrafiotis’ Leadership in Bringing Xcellerate® Informatics to Market Demonstrates How Software Can Improve Health and Improve Lives

IDG’s Computerworld recently recognized Dimitris Agrafiotis, PhD, chief data officer and Computerworld Dimitris Agrafiotis head of technology products for Covance Drug Development, as a 2017 Premier 100 Technology Leaders honoree. This year’s Premier 100 spotlights 100 leaders from both the technology and business sides of companies for their exceptional technology leadership and innovative approaches to business challenges. Covance is the drug development business of LabCorp.

“The Premier 100 awards program highlights the exceptional work of an elite group of IT executives who are leading their organizations through times of unprecedented change. They are using technology to drive high-stakes business projects and create dynamic growth in their organizations,” said Scot Finnie, editor in chief of Computerworld.

“These 100 men and women are not only strategic business thinkers, but also team leaders who recognize the importance of recruiting and retaining the brightest talent to enable digital transformation and harness the opportunities of cloud, big data, mobile and social. We’re pleased to recognize their leadership and honor their achievements.” Continue reading

Risk-Based Monitoring – Driving the Evolution of the Clinical Research Associate Role

Over the last 10 years, clinical trials have changed substantially in response to increasing globalization and study complexity, along with new technological capabilities and industry guidelines[1],7. With these noticeable transformations, sponsors are increasingly revisiting their monitoring methods to uncover new efficiencies and develop more robust risk management processes that can enhance ongoing patient safety and data quality.

At the forefront of this movement is risk-based monitoring (RBM) – a broad term for a variety of clinical monitoring methods that combine people, process and technology, enabling project teams and Clinical Research Associates (CRAs) to focus on the most important risks in clinical trials.

Clinical Research Associate Covance CRA Careers

Continue reading

Leveraging Big Data to Improve Clinical Trial Performance

As any drug developer knows, clinical trials generate a lot of raw and electronic data from Leveraging Big Data to Improve Clinical Trial Performance Covance Chinamultiple sources. Yet tracking progress and reviewing results from each separate database can be cumbersome in traditional environments. This “rear-view” mirror approach to monitoring doesn’t support preventative planning to mitigate future risks and can account for 20-30% of a trial’s costs.

Recognizing the opportunity increase efficiency and deliver information faster, Covance created Xcellerate® Monitoring, a platform that integrates clinical trial data to help sponsors proactively decrease the inherent risks associated with clinical trials.

At a recent clinical seminar in China, Dimitris Agrafiotis, PhD, Vice President, Chief Data Officer discussed how Xcellerate Monitoring tracks quality, patient safety and protocol compliance in clinical trials. Continue reading

Clinical Trials and the Growing Importance of Informatics

Demonstrating the efficacy, safety and differential benefit of a new drug relies on collectingClinical Trial Data Xcellerate Informatics Covance Blog and analyzing enormous amounts of data generated in a clinical trial. Yet this process of extracting knowledge from data is often the source of many inefficiencies.

We recently spoke with Dimitris Agrafiotis, PhD, Vice President and Chief Data Officer at Covance to hear his thoughts on how informatics has affected drug development and will continue to transform the pharmaceutical industry.

Q: Why is informatics important in a global context?

More and more major businesses and industries are being run on software and delivered as online services―from movies to agriculture to national defense. Many of the winners of this new economy are Silicon Valley-style technology companies that are invading and overturning established industry structures. Continue reading